21 CFR Part 4 — Regulation of Combination Products: FDA Jurisdiction Assignment, PMOA Determination, and CGMP Dual Compliance for Combination Products

Section 0: Overview — What Are Combination Products & Why Part 4 Matters (§4.1 + FDA guidance context)

Section 0: Overview — What Are Combination Products & Why Part 4 Matters

21 CFR Part 4 — Regulation of Combination Products | FDA | eCFR current

What Are Combination Products? —

Statutory definition, four product types, and real-world examples

Regulatory Text & Summary (English)

Statutory Definition

Under FD&C Act §3(g) (21 U.S.C. §353(g)), the term "combination product" includes:

A product comprising any combination of a drug and a device
A product comprising a combination of a biological product and a device
A product comprising a combination of a drug and a biological product
A product comprising a combination of a drug, device, and a biological product

The product must have two or more regulated article types working together to achieve the product's intended use. The combination may be physical, chemical, or purely functional (cross-labeling).

Four Types of Combination Products

Single-Entity Combination Product — Two or more regulated components physically, chemically, or otherwise combined or mixed and produced as a single entity. The components cannot be separated without affecting the product's function.
Co-Packaged Combination Product — Two or more separate products packaged together in a single container or as a unit, where each component retains its own regulatory identity but is intended to be used together.
Cross-Labeled Combination Product — Two or more separate products manufactured separately, distributed separately, but labeled for use together. The labeling of one product references the other as required for safe and effective use.
Investigational Combination Product — Any of the above types when used under an Investigational New Drug (IND) application or Investigational Device Exemption (IDE). Regulatory requirements apply even in the investigational stage.

Real-World Examples

Product	Drug Constituent	Device Constituent	Type	Lead Center

Why Part 4 Was Created — Part 4

Historical context, regulatory gaps, and the creation of OCP

Regulatory Text & Summary (English)

The Problem: Three Centers, One Product

Before Part 4, FDA had three separate centers with distinct regulatory standards, review timelines, and post-market requirements:

CDER (Center for Drug Evaluation and Research) — governed drugs under 21 CFR 210/211
CDRH (Center for Devices and Radiological Health) — governed medical devices under 21 CFR 820 and the Quality System Regulation
CBER (Center for Biologics Evaluation and Research) — governed biologics under 21 CFR 600–680

Combination products fell into regulatory gaps where no center had clear jurisdiction, or they faced duplicative review by multiple centers. This created:

Prolonged and unpredictable review timelines
Inconsistent CGMP requirements across similar products
Manufacturer confusion about which submission pathway to use (NDA, BLA, PMA, 510(k))
Post-market surveillance and adverse event reporting ambiguities

Legislative Solution

The Safe Medical Devices Act of 1990 created §3(g) of the FD&C Act, which required FDA to:

Designate a lead center (primary regulatory jurisdiction) for each combination product
Base the designation on the product's primary mode of action (PMOA)
Ensure consistency and predictability in the designation process

21 CFR Part 4 operationalizes §3(g) by establishing the regulatory procedures for designation, including the formal Request for Designation (RFD) process.

Office of Combination Products (OCP)

The Medical Device User Fee and Modernization Act (MDUFMA) of 2002 established the Office of Combination Products (OCP) within the FDA Commissioner's Office. OCP:

Manages the RFD process and issues binding jurisdictional determinations
Resolves inter-center disputes about jurisdiction
Develops and updates guidance on combination product regulation
Monitors combination product reviews to ensure timely, consistent decisions

Reports annually to Congress on combination product activities

                  "The purpose of Part 4 is to achieve timely and effective premarket review of combination products and to ensure consistent and appropriate post-market regulation of these products." — 21 CFR Part 4, Preamble

OCP

ICA vs. Part 4

0.3

Why Part 4 Matters for CDMOs — Part 4 CDMO

CGMP overlap, quality agreements, and the mAb autoinjector scenario

Regulatory Text & Summary (English)

Four Critical Questions for CDMO Operations

A CDMO manufacturing a sterile injectable drug for a combination product must answer four questions before beginning manufacturing:

Which FDA center leads regulation? — Determines which submission type applies (NDA vs. PMA vs. BLA), which division within FDA reviews the product, and which reviewers have authority over manufacturing-related questions.
Which CGMP applies — or does dual CGMP apply? — Under 21 CFR Part 4 Subpart B (the 2013 CGMP rule), manufacturers of combination products may be subject to both 21 CFR Part 211 (drug CGMP) and 21 CFR Part 820 (Quality System Regulation for devices). The CDMO must know which applies to their specific operations.
How do quality agreements allocate compliance responsibility? — The sponsor (drug/device brand owner) and CDMO must explicitly allocate who is responsible for CGMP compliance for each constituent part. Ambiguity in quality agreements is a direct FDA 483 observation risk.
When do manufacturing changes require prior approval vs. notification? — A change to the drug formulation may require a Prior Approval Supplement (PAS), while the same change to device labeling may only require an Annual Report. The CDMO must follow the change control requirements of the lead center.

CDMO Scenario: mAb Autoinjector Sterile Fill-Finish

A CDMO performs sterile fill-finish for a monoclonal antibody (mAb) in a prefilled autoinjector pen. The product is a single-entity combination product: biologic drug (mAb) + device (autoinjector mechanism + prefilled syringe).

Question	Analysis	Implication for CDMO

| Lead center? | mAb is the PMOA CBER or CDER (mAbs transferred to CDER in 2003) | CDER leads; BLA is the likely submission; CMC review under CDER standards |

| Which CGMP? | 21 CFR Part 4 Subpart B: both 21 CFR 211 (drug) and 21 CFR 820 (device) may apply to the combination | CDMO must document how its QMS covers both 211 and 820 requirements for the prefilled syringe/autoinjector components |

| Device CGMP responsibility? | Autoinjector device constituent parts require Design History File (DHF), Device History Record (DHR) under 21 CFR 820 | Quality agreement must specify whether sponsor or CDMO maintains the DHF/DHR; CDMO must confirm its QMS is 820-compatible |

| Change control? | Changes to the prefilled syringe design (e.g., new needle gauge) may require a PAS for the BLA | CDMO change control SOP must route device component changes through sponsor's BLA change management process |

Common CDMO Trap

Assuming only drug CGMP (21 CFR 211) applies when manufacturing the drug constituent for a combination product. Under 21 CFR Part 4 Subpart B, if the CDMO also assembles or tests device constituent parts, the quality system must also satisfy relevant provisions of 21 CFR 820. This is frequently flagged in FDA inspections of CDMOs filling combination product presentations.

CDMO CGMP

Relationship to Other Regulations —

Cross-reference map: Part 4 Part 3 CGMP regulations; what Part 4 does NOT govern

Regulatory Text & Summary (English)

Cross-Reference Map

21 CFR Part 4 does not operate in isolation. It is part of a regulatory framework that must be read in conjunction with several other parts of the CFR:

Regulation	Title / Purpose	Relationship to Part 4

                            ****

| 21 CFR Part 3 | Product Jurisdiction — Procedures for designating the lead center | Part 4 references Part 3 for the formal RFD mechanism and jurisdictional order procedures |

                            ****

| 21 CFR Part 211 | Current Good Manufacturing Practice for Finished Pharmaceuticals | Applies to drug constituent parts; under Part 4 Subpart B, may apply to full combination product when drug CGMP is applicable |

                            ****

| 21 CFR Part 820 | Quality System Regulation (Device CGMP) | Applies to device constituent parts; under Part 4 Subpart B, may apply to combination products where device CGMP is applicable |

                            ****

| 21 CFR Parts 600–680 | Biologics Standards and CGMP | Applies to biological product constituent parts; Part 4 determines whether CBER or CDER leads biologics-containing combination products |

                            ****

| 21 CFR Part 4 Subpart B | Current Good Manufacturing Practice Requirements for Combination Products (2013) | Specifies how CGMP requirements from 211, 820, and 600s apply to combination products and how manufacturers may comply with streamlined provisions |

What Part 4 Does NOT Govern

Part 4 is frequently misunderstood as covering the entire regulatory lifecycle of combination products. It does not:

Govern approval pathways — NDA (21 CFR Part 314), BLA (21 CFR Part 601), PMA (21 CFR Part 814), and 510(k) (21 CFR Part 807) are governed by their respective regulations. Part 4 only determines which center manages those pathways.
Establish submission formats — The Common Technical Document (CTD) format and electronic submission requirements are set by the lead center, not Part 4.
Define safety standards — Biocompatibility (ISO 10993), sterility, container-closure integrity, and other technical standards are governed by USP, ISO, and center-specific guidance, not Part 4.
Override other CFR requirements — Part 4 operates alongside existing requirements; it does not supersede 21 CFR 211, 820, or 600.

21 CFR Part 4 Subpart B (2013 CGMP Rule)

The most operationally significant addition to Part 4 was the 2013 final rule establishing Subpart B: Current Good Manufacturing Practice Requirements for Combination Products. Key provisions:

Manufacturers must comply with the CGMP requirements applicable to each constituent part
A manufacturer complying with one set of CGMP requirements (e.g., 21 CFR 820) may demonstrate compliance with certain overlapping requirements from another set (e.g., 21 CFR 211) using its own CGMP system
The rule provides a streamlined compliance pathway to reduce dual-CGMP burden while maintaining safety and quality
Applies to all combination products subject to FDA premarket review

Part 4

                            **FD&C Act §3(g)**  







                            **21 CFR Part 3**  







                            **21 CFR Part 4**  









                                **21 CFR 211**  




                                **21 CFR 820**  




                                **21 CFR 600s**

Part 4 —

2013 Subpart B CGMP

—

Section Summary —

Key takeaways from Section 0

Key Takeaways (English)

What You Should Know After This Section

1. Definition and Types

A combination product under FD&C Act §3(g) is any product combining two or more of the following: drug, device, biological product. There are four operational types: single-entity, co-packaged, cross-labeled, and investigational.

2. Why Part 4 Exists

Part 4 was created to resolve the pre-1990 problem of combination products falling between FDA's three separate centers (CDER, CDRH, CBER). The 1990 Safe Medical Devices Act mandated lead center designation based on primary mode of action. OCP (est. 2002) enforces this through the RFD process.

3. CGMP Complexity for Manufacturers

Under Part 4 Subpart B (2013), combination product manufacturers may need to comply with both 21 CFR 211 and 21 CFR 820. The streamlined compliance pathway allows a single QMS to satisfy both if equivalence is documented. CDMOs must never assume only drug CGMP applies.

4. What Part 4 Does NOT Do

Part 4 designates jurisdiction — it does not set approval pathways (NDA/BLA/PMA), technical standards, or override other CFR requirements. It is a jurisdictional and procedural rule, not a manufacturing or submission standard.

5. CDMO Practical Implication

Before accepting any combination product contract, a CDMO must confirm: lead center designation, applicable CGMP regulations, quality agreement allocation of responsibilities, and change control routing for device constituent parts.

1. 2. Part 4

3. CGMP

4. Part 4

5. CDMO

            21 CFR Part 3 (Product Jurisdiction Order procedures) |
            21 CFR Part 4 §4.3 (Subpart A: Designation procedures) |
            21 CFR Part 4 §4.4 (Subpart B: CGMP requirements) |
            21 CFR Part 211 (Drug CGMP) |
            21 CFR Part 820 (Device Quality System Regulation) |
            21 CFR Parts 600–680 (Biologics)

21 CFR Part 4 — Regulation of Combination Products | FDA eCFR

SterileGMP Knowledge Hub | Educational Use Only — Not Legal Advice

Last Updated: 2026-04-14

Section 1: §4.1–4.3 — Definitions, Types & Applicable Regulations (§§ 4.1–4.3)

Section 1: §4.1–4.3 — Definitions, Types & Applicable Regulations

21 CFR Part 4 — Regulation of Combination Products | FDA | §§ 4.1–4.3

§4.1 — Scope.

(a) This subpart applies to combination products as defined in §3.2(e) of this chapter. It establishes, for purposes of the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, which current good manufacturing practice (CGMP) requirements in parts 4, 210, 211, 600 through 680, and 820 of this chapter apply to combination products, and provides for the assignment of combination products to a component of FDA.

(b) This subpart does not cover biological products that are regulated solely under the Public Health Service Act and that do not have a drug or device constituent part.

(c) Agreements and decisions made under this part regarding which CGMP requirements apply to a specific combination product are intended to promote the efficient and timely review of applications and the timely compliance of manufacturers with applicable CGMP requirements.

        "This subpart applies to combination products as defined in §3.2(e) of this chapter."

— 21 CFR §4.1(a)

Key cross-references:

§3.2(e) — Definition of "combination product" (the operative definition)
Parts 210, 211 — Drug CGMPs (manufacturing and finished product)
Parts 600–680 — Biological product regulations
Part 820 — Device Quality System Regulation / QMSR
21 CFR Part 3 — Product Jurisdiction (designation authority)

Section 2: §4.5–4.9 — RFD Process, PMOA Determination & Center Assignment (§§ 4.5–4.9)

Section 2: §4.5–4.9 — RFD Process, PMOA Determination & Center Assignment

21 CFR Part 4 — Regulation of Combination Products | FDA | §§ 4.5–4.9 (+ 21 CFR Part 3 §§3.7–3.10)

§4.5 — Agreement, Determination, and Designation Procedures.

Under 21 CFR §3.4 and §4.5, a manufacturer or sponsor seeking to determine which FDA center has primary jurisdiction over a combination product has three procedural options:

Option 1 — Informal OCP Consultation (Non-binding)

    A sponsor may contact OCP informally to discuss product classification questions. OCP staff will provide informal guidance based on precedent products and existing regulatory determinations. This path is fastest and costs no application time, but the response is not a formal designation and does not bind FDA.

Option 2 — Pre-RFD Meeting

    Before filing a formal RFD, a sponsor may request a pre-RFD meeting with OCP to discuss the product's constituent parts, proposed PMOA, and likely center assignment. This meeting clarifies whether a formal RFD is warranted and helps the sponsor prepare a stronger submission. Pre-RFD meetings are especially useful when the PMOA is scientifically ambiguous.

Option 3 — Formal Request for Designation (RFD)

    A sponsor files a written RFD with OCP under §3.7. FDA must respond within 60 calendar days. The designation issued is binding on FDA and establishes the lead center for the product's lifecycle. Filing an RFD is strongly recommended before submitting the first marketing application (IND, NDA, BLA, or PMA).

When to file formal RFD vs. proceed directly:

File formal RFD when: PMOA is unclear; no clear precedent product exists; the product spans two or more center jurisdictions; sponsor needs binding confirmation for regulatory strategy
Proceed directly to lead center when: prior OCP informal guidance is consistent; the product is nearly identical to a previously designated combination product; the primary constituent part classification is unambiguous

Section 3: §4.10–4.11 — CGMP Dual Compliance, Post-Market Obligations & CDMO Responsibilities (§§ 4.10–4.11)

Section 3: §4.10–4.11 — CGMP Dual Compliance, Post-Market Obligations & CDMO Responsibilities

21 CFR Part 4 — Regulation of Combination Products | FDA | §§ 4.10–4.11

Regulatory Framework

§ 4.4 Current good manufacturing practice requirements.

    21 CFR Part 4 Subpart B establishes CGMP requirements for combination products. The 2013 Final Rule (effective December 22, 2013) clarified how manufacturers demonstrate compliance when a combination product includes both drug and device constituents.

§4.4(a) — Default Dual Compliance Rule

The default rule is straightforward: a combination product must comply with the CGMP regulations applicable to each constituent part.

If the combination product includes a drug constituent part must comply with 21 CFR Parts 210 and 211 (drug CGMP)
If the combination product includes a device constituent part must comply with 21 CFR Part 820 (Quality System Regulation / QSR)
If the combination product includes a biological product constituent part must also comply with 21 CFR Parts 600–680
If a combination product includes all three types all three sets of CGMP requirements apply

§4.4(b) — The Streamlined Approach

The streamlined approach is the practical pathway for most manufacturers. Under §4.4(b), a manufacturer may comply with only one set of CGMP regulations — either Part 211 or Part 820 as the primary framework — provided the manufacturer demonstrates that the controls established under the primary CGMP framework satisfy the requirements of the other applicable CGMP regulation.

Key operational requirement: The manufacturer must document how each applicable requirement from the non-primary CGMP set is satisfied by the primary system. This documentation is the gap analysis crosswalk — FDA will review it during inspection.

§4.4(b) — What "Streamlined" Does NOT Mean

Critically, "streamlined" does not mean the manufacturer can ignore requirements that exist only in one regulation and not the other. If a requirement is unique to one regulation with no functional equivalent in the other, that unique requirement must still be implemented. The streamlined approach only allows avoiding literal duplication of procedures when the same outcome is already achieved through an existing system.

        "A person who manufactures or processes a combination product may satisfy the current good manufacturing practice requirements applicable to the combination product by complying with either the drug current good manufacturing practice regulations in parts 210 and 211 of this chapter or the device quality system regulation in part 820 of this chapter, provided the person demonstrates that compliance with that regulation satisfies the requirements of the other applicable regulation(s)."

— 21 CFR §4.4(b), the streamlined compliance option

2013 Final Rule — FDA's Operational Guidance

The 2013 Final Rule clarified several key implementation questions:

FDA confirmed that the lead center's CGMP framework should typically serve as the primary CGMP system
The crosswalk documentation does not need to be a separate standalone document — it may be embedded in SOPs, quality agreements, or the Quality Manual
FDA's "Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products" (January 2017) provides detailed guidance on implementing the streamlined approach
FDA confirmed that both CDRH and CDER/CBER may conduct inspections of a single site manufacturing combination products